Anti-Ret (phospho Y1062)抗体(ab51103)


  • 产品名称Anti-Ret (phospho Y1062)抗体
    参阅全部 Ret 一抗
  • 描述
    兔多克隆抗体to Ret (phospho Y1062)
  • 特异性ab51103 detects endogenous levels of Ret only when phosphorylated at tyrosine 1062.
  • 经测试应用适用于: IHC-P, ICC/IF, WB, ELISAmore details
  • 种属反应性
    与反应: Human
    预测可用于: Mouse, Rat
  • 免疫原

    A synthetic phospho-peptide derived from human Ret around the phosphorylation site of tyrosine 1062 (K-L-YP-G-M).

  • 阳性对照
    • K562 cell extracts




Our Abpromise guarantee covers the use of ab51103 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
IHC-P Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration. PubMed: 24778213
WB 1/500 - 1/1000. Predicted molecular weight: 124 kDa.
ELISA 1/10000.


  • 功能Probable receptor with tyrosine-protein kinase activity; important for development.
  • 疾病相关Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].
    Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.
    Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.
    Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.
    Defects in RET are a cause of susceptibility to pheochromocytoma (PCC) [MIM:171300]. A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
    Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also known as multiple neoplasia type 2 (MEN2). MEN2A is the most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.
    Defects in RET are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=Chromosomal aberrations involving RET are found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. A chromosomal aberration involving TRIM27/RFP is found in thyroid papillary carcinomas. Translocation t(6;10)(p21.3;q11.2) with RET. The translocation generates TRIM27/RET and delta TRIM27/RET oncogenes.
    Defects in RET are a cause of renal adysplasia (RADYS) [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.
    Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.
  • 序列相似性Belongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 1 cadherin domain.
    Contains 1 protein kinase domain.
  • 翻译后修饰Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062.
  • 细胞定位Membrane.
  • Information by UniProt
  • 数据库链接
  • 别名
    • C ret antibody
    • Cadherin family member 12 antibody
    • Cadherin related family member 16 antibody
    • CDHF 12 antibody
    • CDHF12 antibody
    • CDHR16 antibody
    • ELKS Fusion gene antibody
    • HSCR 1 antibody
    • HSCR1 antibody
    • Hydroxyaryl protein kinase antibody
    • MEN2A antibody
    • MEN2B antibody
    • MTC 1 antibody
    • MTC1 antibody
    • Multiple endocrine neoplasia and medullary thyroid carcinoma 1 antibody
    • Oncogene RET antibody
    • Proto oncogene tyrosine protein kinase receptor ret antibody
    • Proto-oncogene c-Ret antibody
    • Proto-oncogene tyrosine-protein kinase receptor ret antibody
    • PTC antibody
    • RET antibody
    • RET ELE1 antibody
    • Ret Proto oncogene antibody
    • RET transforming sequence antibody
    • RET_HUMAN antibody
    • RET51 antibody
    • RET9 antibody
    • tyrosine-protein kinase receptor ret antibody
    see all

Anti-Ret (phospho Y1062) antibody 图像

  • All lanes : Anti-Ret (phospho Y1062) antibody (ab51103) at 1/500 dilution

    Lane 1 : K562 cell lysate.
    Lane 2 : K562 cell Lysate. For this panel, ab51103 was pre-incubated with immunizing peptide.

    Predicted band size : 124 kDa
  • Ab51103 staining human normal testis tissue. Staining is localised to cell membranes.
    Left panel: with primary antibody at 1 ug/ml. Right panel: isotype control.
    Sections were stained using an automated system (DAKO Autostainer Plus), at room temperature: sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer EDTA pH 9.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.

Anti-Ret (phospho Y1062) antibody (ab51103)参考文献

This product has been referenced in:
  • He S  et al. GFRa1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. Proc Natl Acad Sci U S A 111:E2008-17 (2014). ICC/IF . Read more (PubMed: 24778213) »

See 1 Publication for this product

Product Wall

Thank you for your participation in Abcam's follow up survey.

I learned that the protocol tips we had discussed did not solve the problem. I am very sorry to hear that.
Please let me know if any improvement of the resultswas seen at all,...

Read More

Thank you for contacting us. I am sorry to hear that the antibody is not working as expected. I have attached our IHC-P protocol (which includes the section about the antigen retrieval methods) to this email. Also, as we discussed - besides tryi...

Read More